In the interview several topics were touched, such as what the viral vectors are, where they come from and how they are produced, and what they are used for. It was mentioned how 60% of the gene therapy trials try to cure cancer with great success, without forgetting the monogenic diseases, among them the rare diseases, which have served to show the efficacy of these therapies.

VIVEbiotech is a company specialized in the manufacture of lentiviral vectors for human use, whose cutting-edge projects have been recognized with the European Union Seal of Excellence. It thus attends to the growing list of international promoters of clinical trials in this sector who have already carried out promising preclinical studies and want to transfer their therapies to humans.

To listen to the program you can click here.